OMDA
Get informed when a big investor buys or sells
+ FollowOvervalued by 165.7% based on the discounted cash flow analysis.
| Market cap | $1.02 Billion |
|---|---|
| Enterprise Value | $836.54 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.22 |
| Beta | 2.09 |
| Outstanding Shares | 58,923,000 |
| P/E Ratio | -160.31 |
|---|---|
| PEG | 160.31 |
| Price to Sales | 4.29 |
| Price to Book Ratio | 5.71 |
| Enterprise Value to Revenue | 2.95 |
| Enterprise Value to EBIT | -48.77 |
| Enterprise Value to Net Income | -5504 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | 0.13 |
No data
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0335▼ 58.34% |
|---|---|
| Total Calls | 1,228,100▲ 2859.28% |
| Total Puts | 41,100▲ 60.55% |
Holdings and activity of institutional investors.
| Ownership % | 82.43%▼ 2.41% |
|---|---|
| Total Invested | $605.12M▼ 14.66% |
| Investors Holding | 144▲ 8.00% |
No data
Omada Health is a U.S.-based virtual-care provider offering clinically validated programs for chronic conditions like cardiometabolic disease, musculoskeletal care, and behavioral health—delivered digitally between doctor visits.
Controls Medicare and Medicaid reimbursement policy; coverage of digital health for chronic conditions is the single largest driver of Omada's long-term valuation.
Allocates the specific funds for CDC and VA programs that Omada relies on for government-sector revenue.
Primary regulator for the FDA and NIH; directly impacts the regulatory path for digital therapeutics and clinical validation of virtual care.
Focuses on chronic conditions like diabetes and heart disease, which are Omada's primary clinical focus areas, creating significant headline and policy risk.
The VA is one of the largest adopters of virtual care and remote patient monitoring; policy shifts here directly affect the market for chronic care providers.